In addition to the differentiation in antitumor cytotoxic CAR-T cells, a recent study has highlighted the development of human iPSC-derived CAR-engineered CD4+ regulatory T cell (Treg)-like cells for the management of GvHD in a xenograft model [61]. Here, CD4 is linked to graft versus host disease.